Rabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux disease
The purpose of this study was to assess the effect of rabeprazole 20 mg once a day on patient-reported health-related quality of life in routine clinical practice. Patients with erosive gastroesophageal reflux disease participating in an open-label, 8-week study completed the SF-36 Health Survey bef...
Gespeichert in:
| Veröffentlicht in: | Digestive diseases and sciences 2002-11, Vol.47 (11), p.2574-2578 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2578 |
|---|---|
| container_issue | 11 |
| container_start_page | 2574 |
| container_title | Digestive diseases and sciences |
| container_volume | 47 |
| creator | Johanson, John F Siddique, Reshmi Damiano, Anne M Jokubaitis, Leonard Murthy, Anita Bhattacharjya, Ashoke |
| description | The purpose of this study was to assess the effect of rabeprazole 20 mg once a day on patient-reported health-related quality of life in routine clinical practice. Patients with erosive gastroesophageal reflux disease participating in an open-label, 8-week study completed the SF-36 Health Survey before and after treatment with rabeprazole. For all SF-36 scales, there was a statistically significant (p < or = 0.007) improvement in mean scores from baseline to week 8. Improvements in each of the subscales, except for physical functioning, general health, and mental health, were at least 5% in magnitude, a level considered clinically meaningful. Furthermore, while baseline scores were significantly poorer than general United States population scores, follow-up scores for four of the subscales (role limitations due to physical problems, social functioning, role limitations due to emotional problems, and mental health) were comparable to general population scores. In conclusion, rabeprazole significantly improved health-related quality of life in erosive gastroesophageal reflux disease patients and restored social functioning and emotional well-being to levels comparable to those observed in the United States general population. |
| doi_str_mv | 10.1023/A:1020532714664 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_72712525</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>390330301</sourcerecordid><originalsourceid>FETCH-LOGICAL-c280t-c0c5ccf1371789fdfb60798d6111363b9c6c913a36cf4ea03f27997f171d6c503</originalsourceid><addsrcrecordid>eNpdkMFLHDEYxYNU3K169lZCD95G8yWTZNKbLLUVFgSx5yGb-eJGsjtjkrHav95At5ee3jv8eLz3CLkAdgWMi-ubb1WYFFxDq1R7RJYgtWi4VN0nsmSgqgdQC_I552fGmNGgTsgCeCu5MHpJ4oPd4JTsnzEiDbspja-Y6RZtLNsmYbQFB_oy2xjKOx09jcFXbk8nWwLuS6a_Q9lSTGMOr0ifbC5pxDxOW_tUM2hCH-c3OoSMNuMZOfY2Zjw_6Cn5dfv9cfWzWd__uFvdrBvHO1Yax5x0zoPQoDvjB79RTJtuUAAglNgYp5wBYYVyvkXLhOfaGO1Bw6CcZOKUXP7NrXNeZsyl34XsMEa7x3HOva53ccllBb_-Bz6Pc9rXbj2HVohWdqZCXw7QvNnh0E8p7Gx67_-dKD4AkG50xQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>214334589</pqid></control><display><type>article</type><title>Rabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux disease</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Johanson, John F ; Siddique, Reshmi ; Damiano, Anne M ; Jokubaitis, Leonard ; Murthy, Anita ; Bhattacharjya, Ashoke</creator><creatorcontrib>Johanson, John F ; Siddique, Reshmi ; Damiano, Anne M ; Jokubaitis, Leonard ; Murthy, Anita ; Bhattacharjya, Ashoke</creatorcontrib><description>The purpose of this study was to assess the effect of rabeprazole 20 mg once a day on patient-reported health-related quality of life in routine clinical practice. Patients with erosive gastroesophageal reflux disease participating in an open-label, 8-week study completed the SF-36 Health Survey before and after treatment with rabeprazole. For all SF-36 scales, there was a statistically significant (p < or = 0.007) improvement in mean scores from baseline to week 8. Improvements in each of the subscales, except for physical functioning, general health, and mental health, were at least 5% in magnitude, a level considered clinically meaningful. Furthermore, while baseline scores were significantly poorer than general United States population scores, follow-up scores for four of the subscales (role limitations due to physical problems, social functioning, role limitations due to emotional problems, and mental health) were comparable to general population scores. In conclusion, rabeprazole significantly improved health-related quality of life in erosive gastroesophageal reflux disease patients and restored social functioning and emotional well-being to levels comparable to those observed in the United States general population.</description><identifier>ISSN: 0163-2116</identifier><identifier>EISSN: 1573-2568</identifier><identifier>DOI: 10.1023/A:1020532714664</identifier><identifier>PMID: 12452397</identifier><identifier>CODEN: DDSCDJ</identifier><language>eng</language><publisher>United States: Springer Nature B.V</publisher><subject>2-Pyridinylmethylsulfinylbenzimidazoles ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Benzimidazoles - therapeutic use ; Enzyme Inhibitors - therapeutic use ; Female ; Gastroesophageal Reflux - drug therapy ; Health Status Indicators ; Humans ; Male ; Middle Aged ; Omeprazole - analogs & derivatives ; Quality of Life ; Rabeprazole</subject><ispartof>Digestive diseases and sciences, 2002-11, Vol.47 (11), p.2574-2578</ispartof><rights>Copyright Kluwer Academic Publishers Nov 2002</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c280t-c0c5ccf1371789fdfb60798d6111363b9c6c913a36cf4ea03f27997f171d6c503</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12452397$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Johanson, John F</creatorcontrib><creatorcontrib>Siddique, Reshmi</creatorcontrib><creatorcontrib>Damiano, Anne M</creatorcontrib><creatorcontrib>Jokubaitis, Leonard</creatorcontrib><creatorcontrib>Murthy, Anita</creatorcontrib><creatorcontrib>Bhattacharjya, Ashoke</creatorcontrib><title>Rabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux disease</title><title>Digestive diseases and sciences</title><addtitle>Dig Dis Sci</addtitle><description>The purpose of this study was to assess the effect of rabeprazole 20 mg once a day on patient-reported health-related quality of life in routine clinical practice. Patients with erosive gastroesophageal reflux disease participating in an open-label, 8-week study completed the SF-36 Health Survey before and after treatment with rabeprazole. For all SF-36 scales, there was a statistically significant (p < or = 0.007) improvement in mean scores from baseline to week 8. Improvements in each of the subscales, except for physical functioning, general health, and mental health, were at least 5% in magnitude, a level considered clinically meaningful. Furthermore, while baseline scores were significantly poorer than general United States population scores, follow-up scores for four of the subscales (role limitations due to physical problems, social functioning, role limitations due to emotional problems, and mental health) were comparable to general population scores. In conclusion, rabeprazole significantly improved health-related quality of life in erosive gastroesophageal reflux disease patients and restored social functioning and emotional well-being to levels comparable to those observed in the United States general population.</description><subject>2-Pyridinylmethylsulfinylbenzimidazoles</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Benzimidazoles - therapeutic use</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Female</subject><subject>Gastroesophageal Reflux - drug therapy</subject><subject>Health Status Indicators</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Omeprazole - analogs & derivatives</subject><subject>Quality of Life</subject><subject>Rabeprazole</subject><issn>0163-2116</issn><issn>1573-2568</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkMFLHDEYxYNU3K169lZCD95G8yWTZNKbLLUVFgSx5yGb-eJGsjtjkrHav95At5ee3jv8eLz3CLkAdgWMi-ubb1WYFFxDq1R7RJYgtWi4VN0nsmSgqgdQC_I552fGmNGgTsgCeCu5MHpJ4oPd4JTsnzEiDbspja-Y6RZtLNsmYbQFB_oy2xjKOx09jcFXbk8nWwLuS6a_Q9lSTGMOr0ifbC5pxDxOW_tUM2hCH-c3OoSMNuMZOfY2Zjw_6Cn5dfv9cfWzWd__uFvdrBvHO1Yax5x0zoPQoDvjB79RTJtuUAAglNgYp5wBYYVyvkXLhOfaGO1Bw6CcZOKUXP7NrXNeZsyl34XsMEa7x3HOva53ccllBb_-Bz6Pc9rXbj2HVohWdqZCXw7QvNnh0E8p7Gx67_-dKD4AkG50xQ</recordid><startdate>200211</startdate><enddate>200211</enddate><creator>Johanson, John F</creator><creator>Siddique, Reshmi</creator><creator>Damiano, Anne M</creator><creator>Jokubaitis, Leonard</creator><creator>Murthy, Anita</creator><creator>Bhattacharjya, Ashoke</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>200211</creationdate><title>Rabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux disease</title><author>Johanson, John F ; Siddique, Reshmi ; Damiano, Anne M ; Jokubaitis, Leonard ; Murthy, Anita ; Bhattacharjya, Ashoke</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c280t-c0c5ccf1371789fdfb60798d6111363b9c6c913a36cf4ea03f27997f171d6c503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>2-Pyridinylmethylsulfinylbenzimidazoles</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Benzimidazoles - therapeutic use</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Female</topic><topic>Gastroesophageal Reflux - drug therapy</topic><topic>Health Status Indicators</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Omeprazole - analogs & derivatives</topic><topic>Quality of Life</topic><topic>Rabeprazole</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Johanson, John F</creatorcontrib><creatorcontrib>Siddique, Reshmi</creatorcontrib><creatorcontrib>Damiano, Anne M</creatorcontrib><creatorcontrib>Jokubaitis, Leonard</creatorcontrib><creatorcontrib>Murthy, Anita</creatorcontrib><creatorcontrib>Bhattacharjya, Ashoke</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Digestive diseases and sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Johanson, John F</au><au>Siddique, Reshmi</au><au>Damiano, Anne M</au><au>Jokubaitis, Leonard</au><au>Murthy, Anita</au><au>Bhattacharjya, Ashoke</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux disease</atitle><jtitle>Digestive diseases and sciences</jtitle><addtitle>Dig Dis Sci</addtitle><date>2002-11</date><risdate>2002</risdate><volume>47</volume><issue>11</issue><spage>2574</spage><epage>2578</epage><pages>2574-2578</pages><issn>0163-2116</issn><eissn>1573-2568</eissn><coden>DDSCDJ</coden><abstract>The purpose of this study was to assess the effect of rabeprazole 20 mg once a day on patient-reported health-related quality of life in routine clinical practice. Patients with erosive gastroesophageal reflux disease participating in an open-label, 8-week study completed the SF-36 Health Survey before and after treatment with rabeprazole. For all SF-36 scales, there was a statistically significant (p < or = 0.007) improvement in mean scores from baseline to week 8. Improvements in each of the subscales, except for physical functioning, general health, and mental health, were at least 5% in magnitude, a level considered clinically meaningful. Furthermore, while baseline scores were significantly poorer than general United States population scores, follow-up scores for four of the subscales (role limitations due to physical problems, social functioning, role limitations due to emotional problems, and mental health) were comparable to general population scores. In conclusion, rabeprazole significantly improved health-related quality of life in erosive gastroesophageal reflux disease patients and restored social functioning and emotional well-being to levels comparable to those observed in the United States general population.</abstract><cop>United States</cop><pub>Springer Nature B.V</pub><pmid>12452397</pmid><doi>10.1023/A:1020532714664</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0163-2116 |
| ispartof | Digestive diseases and sciences, 2002-11, Vol.47 (11), p.2574-2578 |
| issn | 0163-2116 1573-2568 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72712525 |
| source | MEDLINE; SpringerNature Journals |
| subjects | 2-Pyridinylmethylsulfinylbenzimidazoles Adolescent Adult Aged Aged, 80 and over Benzimidazoles - therapeutic use Enzyme Inhibitors - therapeutic use Female Gastroesophageal Reflux - drug therapy Health Status Indicators Humans Male Middle Aged Omeprazole - analogs & derivatives Quality of Life Rabeprazole |
| title | Rabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T19%3A11%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rabeprazole%20improves%20health-related%20quality%20of%20life%20in%20patients%20with%20erosive%20gastroesophageal%20reflux%20disease&rft.jtitle=Digestive%20diseases%20and%20sciences&rft.au=Johanson,%20John%20F&rft.date=2002-11&rft.volume=47&rft.issue=11&rft.spage=2574&rft.epage=2578&rft.pages=2574-2578&rft.issn=0163-2116&rft.eissn=1573-2568&rft.coden=DDSCDJ&rft_id=info:doi/10.1023/A:1020532714664&rft_dat=%3Cproquest_pubme%3E390330301%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=214334589&rft_id=info:pmid/12452397&rfr_iscdi=true |